Market Access Health, growth & renewal: ABPI 2026 looks to UK’s future The Association of the British Pharmaceutical Industry (ABPI)'s flagship annual conference took place on Thursday, 23rd April.
Market Access The companies shaping the UK’s commercial landscape Which companies are working with the government to implement the US-UK pharmaceutical trade agreement?
News Jazz and Lilly cancer drugs cleared for use by NHS Jazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.
News Multiple myeloma drug Blenrep backed for wider NHS use The revitalisation of GSK's Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.
Market Access Highlights from the UK’s December 2025 VPAG metrics Leela Barham looked at the latest metrics used to monitor the UK’s voluntary pricing scheme.
News NICE update doubles eligible patients for AZ's Lokelma AstraZeneca's hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.